MENLO PARK, Calif., April 23, 2014 /PRNewswire/ -- Neodyne Biosciences, a medical device company focused on the development and commercialization of innovative tissue repair devices to promote healing and minimize scar formation, announced today that embrace® Advanced Scar Therapy will be featured in several key presentations at the Aesthetic Meeting 2014 at the Moscone Center, in San Francisco, Calif.
On Friday, April 25, Geoffrey Gurtner, MD, FACS, Associate Chairman in the Department of Surgery at Stanford University, will present "New Strategies for Preventing Scar Formation" as part of the Premier Global Hot Topics session. The Premier Global Hot Topics Session provides leading plastic surgeons the opportunity to discuss cutting-edge technology, techniques and research on new devices in plastic surgery.
On Monday, April 28, Michael Longaker, MD, FACS, Deane P. and Louise Mitchell Professor in the School of Medicine at Stanford University, will present "A Randomized Controlled Trial of the embrace® Device to Reduce Incisional Scar Formation" during the oral presentations. Also at the Neodyne booth, he will review evidence from a randomized, clinical trial of the embrace® device (IMPROVE), which was recently published in Plastic & Reconstructive Surgery.
For exact presentation times and locations during the Aesthetic Meeting 2014, please refer to the schedule below:
- Friday, April 25
- 6:00pm: "New Strategies for Preventing Scar Formation" Geoffrey Gurtner, MD, FACS. Premier Global Hot Topics S12
- Saturday, April 26
- 10:25am, 12:40pm, and 4:10pm: Recent Clinical Data on embrace® Advanced Scar Therapy - Michael Longaker, MD, FACS. Neodyne Booth #1533
- Sunday, April 27
- 9:25am, 12:10pm, and 4:10pm: Recent Clinical Data on embrace® Advanced Scar Therapy - Michael Longaker, MD, FACS. Neodyne Booth #1533
- Monday, April 28
- 9:23am: "A Randomized Controlled Trial of the embrace® Device to Reduce Incisional Scar Formation" - Michael Longaker, MD, FACS. Scientific Session Orange Room 134
- 9:55am and 12:10pm: Recent Clinical Data on embrace® Advanced Scar Therapy - Michael Longaker, MD, FACS. Neodyne Booth #1533
embrace® Advanced Scar Therapy is the first scar management product of its kind. Each embrace® dressing is an elastomeric device that utilizes a unique mechanism of action to relieve the tension that exists during the skin's natural healing process. embrace® has been proven to significantly improve scar appearance in randomized, controlled trials.1
About Neodyne Biosciences, Inc.
Neodyne Biosciences (www.neodynebio.com) is an evidence based company developing and commercializing innovative tissue repair devices to minimize scar formation, restoring both function and aesthetic appearance. The company is developing stress-shielding devices capable of controlling the mechanical wound environment to ameliorate post-surgical scarring. Although the etiology remains unclear, mechanical forces such as surrounding skin tension and body movement have been demonstrated to increase fibrosis and scar formation. It is estimated that approximately 80 million major surgical procedures are performed in the United States each year and 230 million performed worldwide. Patient frustration with post-surgical scarring spans a variety of procedures with many seeking means of prevention and treatment.
Neodyne Investor Relations Contacts:
1Lim AF, et al. The embrace Device Significantly Decreases Scarring Following Scar Revision Surgery in a Randomized Controlled Trial. Plast Reconstr Surg. 2014;133:398-405.
SOURCE Neodyne Biosciences, Inc.